Literature DB >> 17601796

Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice.

Amir Mohsenin1, Tiejuan Mi, Yang Xia, Rodney E Kellems, Jiang-Fan Chen, Michael R Blackburn.   

Abstract

Adenosine is generated at sites of tissue injury where it serves to regulate inflammation and damage. Adenosine signaling has been implicated in the regulation of pulmonary inflammation and damage in diseases such as asthma and chronic obstructive pulmonary disease; however, the contribution of specific adenosine receptors to key immunoregulatory processes in these diseases is still unclear. Mice deficient in the purine catabolic enzyme adenosine deaminase (ADA) develop pulmonary inflammation and mucous metaplasia in association with adenosine elevations making them a useful model for assessing the contribution of specific adenosine receptors to adenosine-mediated pulmonary disease. Studies suggest that the A(2A) adenosine receptor (A(2A)R) functions to limit inflammation and promote tissue protection; however, the contribution of A(2A)R signaling has not been examined in the ADA-deficient model of adenosine-mediated lung inflammation. The purpose of the current study was to examine the contribution of A(2A)R signaling to the pulmonary phenotype seen in ADA-deficient mice. This was accomplished by generating ADA/A(2A)R double knockout mice. Genetic removal of the A(2A)R from ADA-deficient mice resulted in enhanced inflammation comprised largely of macrophages and neutrophils, mucin production in the bronchial airways, and angiogenesis, relative to that seen in the lungs of ADA-deficient mice with the A(2A)R. In addition, levels of the chemokines monocyte chemoattractant protein-1 and CXCL1 were elevated, whereas levels of cytokines such as TNF-alpha and IL-6 were not. There were no compensatory changes in the other adenosine receptors in the lungs of ADA/A(2A)R double knockout mice. These findings suggest that the A(2A)R plays a protective role in the ADA-deficient model of pulmonary inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17601796     DOI: 10.1152/ajplung.00187.2007

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  23 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  Adenosine signaling and the regulation of chronic lung disease.

Authors:  Yang Zhou; Daniel J Schneider; Michael R Blackburn
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

3.  Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor.

Authors:  Yang Zhou; Amir Mohsenin; Eva Morschl; Hays W J Young; Jose G Molina; Wenbin Ma; Chun-Xiao Sun; Hector Martinez-Valdez; Michael R Blackburn
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

4.  Sustained adenosine exposure causes lung endothelial barrier dysfunction via nucleoside transporter-mediated signaling.

Authors:  Qing Lu; Julie Newton; Vivian Hsiao; Paul Shamirian; Michael R Blackburn; Mesias Pedroza
Journal:  Am J Respir Cell Mol Biol       Date:  2012-06-28       Impact factor: 6.914

Review 5.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

Review 6.  Adenosine receptors in wound healing, fibrosis and angiogenesis.

Authors:  Igor Feoktistov; Italo Biaggioni; Bruce N Cronstein
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Major histocompatibility class II transactivator expression in smooth muscle cells from A2b adenosine receptor knock-out mice: cross-talk between the adenosine and interferon-gamma signaling.

Authors:  Yong Xu; Katya Ravid; Barbara D Smith
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

Review 8.  Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease.

Authors:  Riccardo Polosa; Michael R Blackburn
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

Review 9.  Adenosine signaling during acute and chronic disease states.

Authors:  Harry Karmouty-Quintana; Yang Xia; Michael R Blackburn
Journal:  J Mol Med (Berl)       Date:  2013-01-23       Impact factor: 4.599

10.  Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis.

Authors:  Huan Wang; Weiyu Zhang; Chuhong Zhu; Christoph Bucher; Bruce R Blazar; Chunxiang Zhang; Jiang-Fan Chen; Joel Linden; Chaodong Wu; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-04-30       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.